Article
Surgery
Tobias Veit, Dieter Munker, Juergen Barton, Katrin Milger, Teresa Kauke, Bruno Meiser, Sebastian Michel, Michael Zoller, Hans Nitschko, Oliver T. Keppler, Jurgen Behr, Nikolaus Kneidinger
Summary: This study assessed the therapeutic efficacy of letermovir in lung transplant recipients with difficult to treat CMV infections. Most patients responded rapidly to letermovir treatment, showing significant reduction in CMV viral load and clearance of infection. However, a small percentage of patients developed a mutation conferring resistance to letermovir.
AMERICAN JOURNAL OF TRANSPLANTATION
(2021)
Article
Pharmacology & Pharmacy
Jocelyne Piret, Nathalie Goyette, Guy Boivin
Summary: Letermovir (LTV) exhibits similar susceptibility against clinical HCMV isolates and recombinant viruses with similar drug susceptibility phenotypes to currently-approved DNA polymerase inhibitors or maribavir.
ANTIVIRAL RESEARCH
(2022)
Article
Immunology
Sunwen Chou, Kening Song, Jingyang Wu, Tien Bo, Clyde Crumpacker
Summary: The study identified UL97 mutations T409M, H411Y, or C480F as conferring maribavir resistance in patients receiving maribavir therapy. The newly phenotyped mutation C480F showed high-grade maribavir resistance and low-grade ganciclovir resistance, posing challenges to treatment.
JOURNAL OF INFECTIOUS DISEASES
(2022)
Article
Pharmacology & Pharmacy
Sunwen Chou
Summary: Acyclovir has weak activity against human cytomegalovirus (CMV) and is not the preferred anti-CMV drug due to its limited efficacy. However, in cases where highly cidofovir-resistant exonuclease mutations are present without a simultaneous mutation in UL97, acyclovir may become a therapeutic option as it shows differential susceptibility in certain CMV mutants.
ANTIVIRAL RESEARCH
(2021)
Review
Medicine, Research & Experimental
Jennifer L. Saullo, Rachel A. Miller
Summary: Cytomegalovirus (CMV) is a common viral pathogen in the transplant population and selecting the best preventive strategy depends on various factors. Letermovir (LTV) is a novel CMV therapy that inhibits viral DNA synthesis and lacks side effects and resistance mechanisms. LTV is approved for CMV prevention in adult hematopoietic cell transplant recipients and is being increasingly used off-label. This review summarizes important concepts of CMV management, focusing on LTV pharmacology, clinical experience, and future prospects.
ANNUAL REVIEW OF MEDICINE
(2023)
Article
Hematology
Mathilde Sourisseau, Emmanuel Faure, Helene Behal, Paul Chauvet, Micha Srour, Antoine Capes, Valerie Coiteux, Leonardo Magro, Serge Alfandari, Enagnon Kazali Alidjinou, Nicolas Simon, Fanny Vuotto, Micheline Karam, Karine Faure, Ibrahim Yakoub-Agha, David Beauvais
Summary: Letermovir is an effective drug for CMV infection prophylaxis in adult patients undergoing allo-HCT. A risk-based strategy allows high-risk patients to benefit from letermovir while some low-risk patients can avoid its use.
Article
Pharmacology & Pharmacy
Sunwen Chou, Steven Kleiboeker
Summary: Genotypic testing for letermovir resistance revealed multiple sequence variants, with codon 325 mutations being the most common and capable of causing high-level resistance. Additionally, new mutations were identified, some of which conferred a 2-to 5-fold increase in the drug's inhibitory concentrations. These findings highlight the ongoing concern of the emergence of absolute letermovir resistance during therapy.
ANTIVIRAL RESEARCH
(2022)
Article
Immunology
Robin K. Avery, Sophie Alain, Barbara D. Alexander, Emily A. Blumberg, Roy F. Chemaly, Catherine Cordonnier, Rafael F. Duarte, Diana F. Florescu, Nassim Kamar, Deepali Kumar, Johan Maertens, Francisco M. Marty, Genovefa A. Papanicolaou, Fernanda P. Silveira, Oliver Witzke, Jingyang Wu, Aimee K. Sundberg, Martha Fournier
Summary: In this randomized comparative study, Maribavir was found to be more effective than investigator-assigned treatment for refractory cytomegalovirus infections. Maribavir also had fewer adverse effects in terms of nephrotoxicity, myelotoxicity, and treatment discontinuations.
CLINICAL INFECTIOUS DISEASES
(2022)
Article
Pharmacology & Pharmacy
Steven B. Kleiboeker
Summary: Cytomegalovirus (CMV) is a significant human pathogen, with low but impactful prevalence of drug resistance mutations. In this study, 30.04% of patient samples showed resistance to one or more anti-CMV drugs, with most resistance mutations found in UL97. Rapid monitoring for resistance in suspected cases allows for tailored treatment based on objective results instead of empirical drug selection.
ANTIVIRAL RESEARCH
(2023)
Article
Medicine, General & Internal
Ajit P. Limaye, Klemens Budde, Atul Humar, Flavio Vincenti, Dirk R. J. Kuypers, Robert P. Carroll, Nicole Stauffer, Yoshihiko Murata, Julie M. Strizki, Valerie L. Teal, Christopher L. Gilbert, Barbara A. Haber
Summary: This study compared the efficacy and safety of letermovir with valganciclovir in preventing cytomegalovirus (CMV) disease in kidney transplant recipients. Results showed that letermovir was as effective as valganciclovir in preventing CMV disease over 52 weeks, with lower rates of leukopenia or neutropenia, supporting its use for this indication.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
(2023)
Article
Microbiology
Nicholas T. Streck, Mark J. Espy, Matthew J. Ferber, Eric W. Klee, Raymund R. Razonable, Dimitri Gonzalez, Chalom Sayada, Phillip R. Heaton, Sunwen Chou, Matthew J. Binnicker
Summary: A novel next-generation sequencing (NGS) method was developed and validated in this study to accurately detect mutations in CMV genes associated with antiviral resistance. Compared to traditional Sanger sequencing, the NGS method demonstrated higher consistency and can assist in providing personalized antiviral therapy.
JOURNAL OF CLINICAL MICROBIOLOGY
(2023)
Article
Pharmacology & Pharmacy
Stefan Weinberger, Christoph Steininger
Summary: Polymerase chain reaction (PCR) methods are effective in monitoring viral load in CMV patients, but may overestimate viral load in patients receiving Letermovir (LMV) treatment. This study compared the effects of LMV and Ganciclovir (GCV) treatment on viral DNA levels in infected cells. Results showed that DNase treatment had different effects on cell lysates and cell culture supernatants, suggesting that concatemeric DNA accumulation may confound LMV efficacy evaluation through qPCR.
ANTIVIRAL RESEARCH
(2022)
Article
Biophysics
Garrett A. Perchetti, Melinda A. Biernacki, Hu Xie, Jared Castor, Laurel Joncas-Schronce, Masumi Ueda Oshima, YoungJun Kim, Keith R. Jerome, Brenda M. Sandmaier, Paul J. Martin, Michael Boeckh, Alexander L. Greninger, Danniel Zamora
Summary: The authors evaluated letermovir resistance and breakthrough CMV reactivation in CMV-seropositive HCT recipients receiving letermovir prophylaxis. A rare C325Y resistance mutation was identified, and cumulative steroid exposure was the strongest risk factor for CMV at all viral thresholds. Graft-versus-host disease prophylaxis with post-transplantation cyclophosphamide or calcineurin inhibitors plus mycophenolate were also associated with an increased risk of CMV reactivation.
BONE MARROW TRANSPLANTATION
(2023)
Article
Microbiology
Ana-Belen Perez, Marta Santos Bravo, Elisa Vidal-Verdu, Aurora Paez-Vega, Jose-Manuel Vaquero-Barrios, Jose-Luis Montero, Maria-Angeles Marcos, Julian Torre-Cisneros
Summary: This observation provides comprehensive data on the clinical correlates of using letermovir as secondary prophylaxis in solid organ transplantation. It emphasizes the importance of monitoring CMV disease and early genotypic detection of resistance mutations when using new antiviral drugs for off-label indications in patients experiencing CMV relapses or not responding to standard antiviral therapy. The observations and reviewed bibliography can be helpful for optimizing the use of new treatments for transplant recipients, given the emerging problem of drug-resistant CMV infection.
MICROBIOLOGY SPECTRUM
(2023)
Article
Pharmacology & Pharmacy
Clotilde Muller, Valentin Tilloy, Emilie Frobert, Linda Feghoul, Isabelle Garrigue, Quentin Lepiller, Audrey Mirand, Egor Sidorov, Sebastien Hantz, Sophie Alain
Summary: This study identified mutations in pUL51 in patients non-response to Letermovir therapy. The UL51-A95V mutation was found to confer increased resistance to Letermovir. Modeling analysis suggests potential binding domains for LMV.
ANTIVIRAL RESEARCH
(2022)